BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lindblad A, Glaumann H, Strandvik B. Natural history of liver disease in cystic fibrosis. Hepatology. 1999;30:1151-1158. [PMID: 10534335 DOI: 10.1002/hep.510300527] [Cited by in Crossref: 215] [Cited by in F6Publishing: 178] [Article Influence: 9.3] [Reference Citation Analysis]
Number Citing Articles
1 Dhillon A, Steadman RH. Liver Diseases. Anesthesia and Uncommon Diseases. Elsevier; 2012. pp. 162-214. [DOI: 10.1016/b978-1-4377-2787-6.00005-x] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
2 Khanna R, Alam S, Rastogi A, Sharma CB. Neonatal cholestasis with ductal paucity and steatosis. Indian Pediatr 2013;50:316-20. [DOI: 10.1007/s13312-013-0073-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
3 Knisely A. Paediatric biliary-tract disease. Current Diagnostic Pathology 2002;8:152-9. [DOI: 10.1054/cdip.2002.0110] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
4 De Lisle RC, Borowitz D. The cystic fibrosis intestine. Cold Spring Harb Perspect Med. 2013;3:a009753. [PMID: 23788646 DOI: 10.1101/cshperspect.a009753] [Cited by in Crossref: 95] [Cited by in F6Publishing: 90] [Article Influence: 10.6] [Reference Citation Analysis]
5 Nash KL, Collier JD, French J, McKeon D, Gimson AE, Jamieson NV, Wallwork J, Bilton D, Alexander GJ. Cystic fibrosis liver disease: to transplant or not to transplant? Am J Transplant 2008;8:162-9. [PMID: 17973959 DOI: 10.1111/j.1600-6143.2007.02028.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
6 Alexopoulou A, Pouriki S, Vasilieva L, Alexopoulos T, Filaditaki V, Gioka M, Diamantea F, Dourakis SP. Evaluation of noninvasive markers for the diagnosis of cystic fibrosis liver disease. Scand J Gastroenterol 2018;53:1547-52. [PMID: 30600723 DOI: 10.1080/00365521.2018.1534986] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Henrion-Caude A, Flamant C, Roussey M, Housset C, Flahault A, Fryer AA, Chadelat K, Strange RC, Clement A. Liver disease in pediatric patients with cystic fibrosis is associated with glutathione S-transferase P1 polymorphism. Hepatology 2002;36:913-7. [PMID: 12297838 DOI: 10.1053/jhep.2002.35534] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 2.2] [Reference Citation Analysis]
8 Rowland M, Gallagher CG, O'Laoide R, Canny G, Broderick A, Hayes R, Greally P, Slattery D, Daly L, Durie P, Bourke B. Outcome in cystic fibrosis liver disease. Am J Gastroenterol 2011;106:104-9. [PMID: 20736939 DOI: 10.1038/ajg.2010.316] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 4.2] [Reference Citation Analysis]
9 Behrens CB, Langholz JH, Eiler J, Jenewein R, Naehrlich L, Fuchs K, Harth S, Krombach GA, Alzen GF. A pilot study of the characterization of hepatic tissue strain in children with cystic-fibrosis-associated liver disease (CFLD) by acoustic radiation force impulse imaging. Pediatr Radiol. 2013;43:552-557. [PMID: 23192669 DOI: 10.1007/s00247-012-2560-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
10 Lewindon PJ, Shepherd RW, Walsh MJ, Greer RM, Williamson R, Pereira TN, Frawley K, Bell SC, Smith JL, Ramm GA. Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy. Hepatology 2011;53:193-201. [DOI: 10.1002/hep.24014] [Cited by in Crossref: 68] [Cited by in F6Publishing: 57] [Article Influence: 5.7] [Reference Citation Analysis]
11 Wasuwanich P, Karnsakul W. Cystic fibrosis-associated liver disease in children.Minerva Pediatr. 2020;72:440-447. [PMID: 32418413 DOI: 10.23736/S0026-4946.20.05895-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Van Biervliet S, Vanbillemont G, Van Biervliet J, Declercq D, Robberecht E, Christophe A. Relation between Fatty Acid Composition and Clinical Status or Genotype in Cystic Fibrosis Patients. Ann Nutr Metab 2008;51:541-9. [DOI: 10.1159/000114208] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
13 Palaniappan SK, Than NN, Thein AW, Moe S, van Mourik I. Interventions for preventing and managing advanced liver disease in cystic fibrosis. Cochrane Database Syst Rev 2017;8:CD012056. [PMID: 28850173 DOI: 10.1002/14651858.CD012056.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
14 Singh J, Towns S, Jayasuriya G, Hunt S, Simonds S, Boyton C, Middleton A, Kench A, Pandit C, Keatley LR, Chien J, Bishop J, Song Y, Robinson P, Selvadurai H, Middleton PG, Fitzgerald DA. Transition to adult care in cystic fibrosis: The challenges and the structure. Paediatr Respir Rev 2020:S1526-0542(20)30114-7. [PMID: 32917516 DOI: 10.1016/j.prrv.2020.07.009] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Masson A, Launay O, Delaisi B, Bassinet L, Remus N, Lebourgeois M, Chedevergne F, Bailly C, Foucaud P, Corvol H, deBlic J, Sermet-gaudelus I. Vaccine coverage in CF children: A French multicenter study. Journal of Cystic Fibrosis 2015;14:615-20. [DOI: 10.1016/j.jcf.2015.04.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
16 Sweed N, Kim HJ, Hultenby K, Barros R, Parini P, Sancisi V, Strandvik B, Gabbi C. Liver X receptor β regulates bile volume and the expression of aquaporins and cystic fibrosis transmembrane conductance regulator in the gallbladder. Am J Physiol Gastrointest Liver Physiol 2021;321:G243-51. [PMID: 34259574 DOI: 10.1152/ajpgi.00024.2021] [Reference Citation Analysis]
17 Melzi ML, Kelly DA, Colombo C, Jara P, Manzanares J, Colledan M, Strazzabosco M, DeLorenzo P, Valsecchi MG, Adam R. Liver transplant in cystic fibrosis: a poll among European centers. A study from the European Liver Transplant Registry. Transpl Int. 2006;19:726-731. [PMID: 16918533 DOI: 10.1111/j.1432-2277.2006.00344.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 3.1] [Reference Citation Analysis]
18 Kobelska-Dubiel N, Klincewicz B, Cichy W. Liver disease in cystic fibrosis. Prz Gastroenterol. 2014;9:136-141. [PMID: 25097709 DOI: 10.5114/pg.2014.43574] [Cited by in Crossref: 7] [Cited by in F6Publishing: 21] [Article Influence: 0.9] [Reference Citation Analysis]
19 Ledder O, Haller W, Couper RT, Lewindon P, Oliver M. Cystic fibrosis: an update for clinicians. Part 2: hepatobiliary and pancreatic manifestations. J Gastroenterol Hepatol 2014;29:1954-62. [PMID: 25238538 DOI: 10.1111/jgh.12785] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
20 Freudenberg F, Broderick AL, Yu BB, Leonard MR, Glickman JN, Carey MC. Pathophysiological basis of liver disease in cystic fibrosis employing a DeltaF508 mouse model. Am J Physiol Gastrointest Liver Physiol 2008;294:G1411-20. [PMID: 18436622 DOI: 10.1152/ajpgi.00181.2007] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
21 Gelfond D, Borowitz D. Gastrointestinal complications of cystic fibrosis. Clin Gastroenterol Hepatol. 2013;11:333-342; quiz e30-e31. [PMID: 23142604 DOI: 10.1016/j.cgh.2012.11.006] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 5.2] [Reference Citation Analysis]
22 Brigman C, Feranchak A. Liver involvement in cystic fibrosis. Curr Treat Options Gastro 2006;9:484-96. [DOI: 10.1007/s11938-006-0005-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
23 Lamireau T, Monnereau S, Martin S, Marcotte J, Winnock M, Alvarez F. Epidemiology of liver disease in cystic fibrosis: a longitudinal study. Journal of Hepatology 2004;41:920-5. [DOI: 10.1016/j.jhep.2004.08.006] [Cited by in Crossref: 131] [Cited by in F6Publishing: 99] [Article Influence: 7.3] [Reference Citation Analysis]
24 de Monestrol I, Klint Å, Sparén P, Hjelte L. Age at diagnosis and disease progression of cystic fibrosis in an area without newborn screening: Age at diagnosis of cystic fibrosis. Paediatric and Perinatal Epidemiology 2011;25:298-305. [DOI: 10.1111/j.1365-3016.2010.01162.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
25 Ye W, Narkewicz MR, Leung DH, Karnsakul W, Murray KF, Alonso EM, Magee JC, Schwarzenberg SJ, Weymann A, Molleston JP; CFLDnet research group. Variceal Hemorrhage and Adverse Liver Outcomes in Patients With Cystic Fibrosis Cirrhosis. J Pediatr Gastroenterol Nutr 2018;66:122-7. [PMID: 28906321 DOI: 10.1097/MPG.0000000000001728] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
26 Goss CH, Mayer-Hamblett N, Kronmal RA, Williams J, Ramsey BW. Laboratory parameter profiles among patients with cystic fibrosis. J Cyst Fibros 2007;6:117-23. [PMID: 16829217 DOI: 10.1016/j.jcf.2006.05.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
27 Sun X, Sui H, Fisher JT, Yan Z, Liu X, Cho HJ, Joo NS, Zhang Y, Zhou W, Yi Y, Kinyon JM, Lei-Butters DC, Griffin MA, Naumann P, Luo M, Ascher J, Wang K, Frana T, Wine JJ, Meyerholz DK, Engelhardt JF. Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis. J Clin Invest 2010;120:3149-60. [PMID: 20739752 DOI: 10.1172/JCI43052] [Cited by in Crossref: 253] [Cited by in F6Publishing: 177] [Article Influence: 21.1] [Reference Citation Analysis]
28 Assis DN, Debray D. Gallbladder and bile duct disease in Cystic Fibrosis.J Cyst Fibros. 2017;16 Suppl 2:S62-S69. [PMID: 28986023 DOI: 10.1016/j.jcf.2017.07.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
29 Black SM, Woodley FW, Tumin D, Mumtaz K, Whitson BA, Tobias JD, Hayes D. Cystic Fibrosis Associated with Worse Survival After Liver Transplantation. Dig Dis Sci 2016;61:1178-85. [DOI: 10.1007/s10620-015-3968-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
30 Karlas T, Neuschulz M, Oltmanns A, Güttler A, Petroff D, Wirtz H, Mainz JG, Mössner J, Berg T, Tröltzsch M, Keim V, Wiegand J. Non-invasive evaluation of cystic fibrosis related liver disease in adults with ARFI, transient elastography and different fibrosis scores. PLoS One 2012;7:e42139. [PMID: 22848732 DOI: 10.1371/journal.pone.0042139] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
31 Rosenfeld M, Cunningham S, Harris WT, Lapey A, Regelmann WE, Sawicki GS, Southern KW, Chilvers M, Higgins M, Tian S, Cooke J, Davies JC; KLIMB study group. An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB). J Cyst Fibros 2019;18:838-43. [PMID: 31053538 DOI: 10.1016/j.jcf.2019.03.009] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 12.7] [Reference Citation Analysis]
32 Sasame A, Stokes D, Bourke B, Connolly L, Fitzpatrick E, Rowland M. The impact of liver disease on mortality in cystic fibrosis-A systematic review. J Cyst Fibros 2021:S1569-1993(21)01328-X. [PMID: 34380590 DOI: 10.1016/j.jcf.2021.07.014] [Reference Citation Analysis]
33 Debray D. L'atteinte hépatique de la mucoviscidose. Archives de Pédiatrie 2012;19:S23-6. [DOI: 10.1016/s0929-693x(12)71104-1] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
34 Michl RK, Tabori H, Hentschel J, Beck JF, Mainz JG. Clinical approach to the diagnosis and treatment of cystic fibrosis and CFTR-related disorders. Expert Review of Respiratory Medicine 2016;10:1177-86. [DOI: 10.1080/17476348.2016.1240032] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
35 Calvopina DA, Lewindon PJ, Ramm LE, Noble C, Hartel GF, Leung DH, Ramm GA. Gamma-glutamyl transpeptidase-to-platelet ratio as a biomarker of liver disease and hepatic fibrosis severity in paediatric Cystic Fibrosis. J Cyst Fibros 2021:S1569-1993(21)02171-8. [PMID: 34953741 DOI: 10.1016/j.jcf.2021.10.014] [Reference Citation Analysis]
36 Lewindon PJ, Pereira TN, Hoskins AC, Bridle KR, Williamson RM, Shepherd RW, Ramm GA. The role of hepatic stellate cells and transforming growth factor-beta(1) in cystic fibrosis liver disease. Am J Pathol. 2002;160:1705-1715. [PMID: 12000722 DOI: 10.1016/s0002-9440(10)61117-0] [Cited by in Crossref: 91] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
37 Strandvik B, Björck E, Fallström M, Gronowitz E, Thountzouris J, Lindblad A, Markiewicz D, Wahlström J, Tsui LC, Zielenski J. Spectrum of mutations in the CFTR gene of patients with classical and atypical forms of cystic fibrosis from southwestern Sweden: identification of 12 novel mutations. Genet Test 2001;5:235-42. [PMID: 11788090 DOI: 10.1089/10906570152742290] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
38 Buxbaum J, Nguyen N, Kulkarni S, Palmer S, Rao A, Selby R. Multidisciplinary Treatment of Cystic Fibrosis-Related Recurrent Pyogenic Cholangitis (CF-RPC). Dig Dis Sci 2015;60:1801-4. [DOI: 10.1007/s10620-015-3532-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Eminoglu TF, Polat E, Gökçe S, Ezgü FS, Senel S, Apaydin S. Cystic fibrosis presenting with neonatal cholestasis simulating biliary atresia in a patient with a novel mutation. Indian J Pediatr 2013;80:502-4. [PMID: 22798282 DOI: 10.1007/s12098-012-0842-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
40 Slieker MG, Deckers-kocken JM, Uiterwaal CSPM, van der Ent CK, Houwen RHJ. Risk factors for the development of cystic fibrosis related liver disease. Hepatology 2003;38:775-6. [DOI: 10.1053/jhep.2003.50403] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
41 Bodewes FA, van der Doef HP, Houwen RH, Verkade HJ. Increase of Serum γ-Glutamyltransferase Associated With Development of Cirrhotic Cystic Fibrosis Liver Disease. Journal of Pediatric Gastroenterology & Nutrition 2015;61:113-8. [DOI: 10.1097/mpg.0000000000000758] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
42 Arnon R, Annunziato RA, Miloh T, Padilla M, Sogawa H, Batemarco L, Willis A, Suchy F, Kerkar N. Liver and combined lung and liver transplantation for cystic fibrosis: Analysis of the UNOS database: Liver transplantation for cystic fibrosis. Pediatric Transplantation 2011;15:254-64. [DOI: 10.1111/j.1399-3046.2010.01460.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
43 Iordache L, Gaudelus J, Hubert D, Launay O. Vaccination des patients atteints de mucoviscidose. Archives de Pédiatrie 2012;19:S36-9. [DOI: 10.1016/s0929-693x(12)71108-9] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
44 Lenaerts C, Lapierre C, Patriquin H, Bureau N, Lepage G, Harel F, Marcotte J, Roy CC. Surveillance for cystic fibrosis-associated hepatobiliary disease: early ultrasound changes and predisposing factors. The Journal of Pediatrics 2003;143:343-50. [DOI: 10.1067/s0022-3476(03)00329-9] [Cited by in Crossref: 48] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
45 Bodewes FA, Bijvelds MJ, de Vries W, Baller JF, Gouw AS, de Jonge HR, Verkade HJ. Cholic acid induces a Cftr dependent biliary secretion and liver growth response in mice. PLoS One 2015;10:e0117599. [PMID: 25680200 DOI: 10.1371/journal.pone.0117599] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
46 Sun X, Olivier AK, Yi Y, Pope CE, Hayden HS, Liang B, Sui H, Zhou W, Hager KR, Zhang Y, Liu X, Yan Z, Fisher JT, Keiser NW, Song Y, Tyler SR, Goeken JA, Kinyon JM, Radey MC, Fligg D, Wang X, Xie W, Lynch TJ, Kaminsky PM, Brittnacher MJ, Miller SI, Parekh K, Meyerholz DK, Hoffman LR, Frana T, Stewart ZA, Engelhardt JF. Gastrointestinal pathology in juvenile and adult CFTR-knockout ferrets. Am J Pathol. 2014;184:1309-1322. [PMID: 24637292 DOI: 10.1016/j.ajpath.2014.01.035] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 5.9] [Reference Citation Analysis]
47 Frerichs C, Smyth A. Treatment strategies for cystic fibrosis: what's in the pipeline? Expert Opinion on Pharmacotherapy 2009;10:1191-202. [DOI: 10.1517/14656560902928896] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
48 Herrmann U, Dockter G, Lammert F. Cystic fibrosis-associated liver disease. Best Pract Res Clin Gastroenterol. 2010;24:585-592. [PMID: 20955961 DOI: 10.1016/j.bpg.2010.08.003] [Cited by in Crossref: 55] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
49 Colombo C, Costantini D, Rocchi A, Romano G, Rossi G, Bianchi ML, Bertoli S, Battezzati A. Effects of liver transplantation on the nutritional status of patients with cystic fibrosis*. Transplant Int 2005;18:246-55. [DOI: 10.1111/j.1432-2277.2004.00013.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
50 Thompson R. Pediatric liver disease: . Current Opinion in Gastroenterology 2000;16:271-4. [DOI: 10.1097/00001574-200005000-00010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
51 Mueller-abt PR, Frawley KJ, Greer RM, Lewindon PJ. Comparison of ultrasound and biopsy findings in children with cystic fibrosis related liver disease. Journal of Cystic Fibrosis 2008;7:215-21. [DOI: 10.1016/j.jcf.2007.08.001] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
52 Wilbert F, Grünert SC, Heinzmann A, Bode SFN. Cystic fibrosis in disguise - the wolf in sheep's clothing, a case report. BMC Pediatr 2021;21:174. [PMID: 33853553 DOI: 10.1186/s12887-021-02636-w] [Reference Citation Analysis]
53 Pals F, Verkade H, Gulmans V, De Koning B, Koot B, De Meij T, Hendriks D, Gierenz N, Vreugdenhil A, Houwen R, Bodewes F. Cirrhosis associated with decreased survival and a 10-year lower median age at death of cystic fibrosis patients in the Netherlands. Journal of Cystic Fibrosis 2019;18:385-9. [DOI: 10.1016/j.jcf.2018.11.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
54 Adler AI, Gunn E, Haworth CS, Bilton D. Characteristics of adults with and without cystic fibrosis-related diabetes. Diabet Med 2007;24:1143-8. [PMID: 17888134 DOI: 10.1111/j.1464-5491.2007.02252.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
55 Dana J, Girard M, Franchi-Abella S, Berteloot L, Benoit-Cherifi M, Imbert-Bismut F, Sermet-Gaudelus I, Debray D. Comparison of Transient Elastography, ShearWave Elastography, Magnetic Resonance Elastography and FibroTest as routine diagnostic markers for assessing liver fibrosis in children with Cystic Fibrosis. Clin Res Hepatol Gastroenterol 2021;:101855. [PMID: 34933150 DOI: 10.1016/j.clinre.2021.101855] [Reference Citation Analysis]
56 Valamparampil JJ, Gupte GL. Cystic fibrosis associated liver disease in children. World J Hepatol 2021; 13(11): 1727-1742 [PMID: 34904041 DOI: 10.4254/wjh.v13.i11.1727] [Reference Citation Analysis]
57 Keiser NW, Engelhardt JF. New animal models of cystic fibrosis: what are they teaching us? Curr Opin Pulm Med 2011;17:478-83. [PMID: 21857224 DOI: 10.1097/MCP.0b013e32834b14c9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 59] [Article Influence: 3.0] [Reference Citation Analysis]
58 Shapiro AJ, Esther CR, Leigh MW, Dellon EP. Vaccine induced Hepatitis A and B protection in children at risk for cystic fibrosis associated liver disease. Vaccine 2013;31:906-11. [DOI: 10.1016/j.vaccine.2012.12.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
59 Turck D, Braegger CP, Colombo C, Declercq D, Morton A, Pancheva R, Robberecht E, Stern M, Strandvik B, Wolfe S. ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clin Nutr. 2016;35:557-577. [PMID: 27068495 DOI: 10.1016/j.clnu.2016.03.004] [Cited by in Crossref: 207] [Cited by in F6Publishing: 156] [Article Influence: 34.5] [Reference Citation Analysis]
60 McKeon D, Day A, Parmar J, Alexander G, Bilton D. Hepatocellular carcinoma in association with cirrhosis in a patient with cystic fibrosis.J Cyst Fibros. 2004;3:193-195. [PMID: 15463908 DOI: 10.1016/j.jcf.2004.04.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
61 Ramm GA, Shepherd RW, Hoskins AC, Greco SA, Ney AD, Pereira TN, Bridle KR, Doecke JD, Meikle PJ, Turlin B. Fibrogenesis in pediatric cholestatic liver disease: role of taurocholate and hepatocyte-derived monocyte chemotaxis protein-1 in hepatic stellate cell recruitment. Hepatology. 2009;49:533-544. [PMID: 19115220 DOI: 10.1002/hep.22637] [Cited by in Crossref: 74] [Cited by in F6Publishing: 77] [Article Influence: 5.7] [Reference Citation Analysis]
62 Debray D, Kelly D, Houwen R, Strandvik B, Colombo C. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J Cyst Fibros. 2011;10 Suppl 2:S29-S36. [PMID: 21658639 DOI: 10.1016/s1569-1993(11)60006-4] [Cited by in Crossref: 233] [Cited by in F6Publishing: 69] [Article Influence: 21.2] [Reference Citation Analysis]
63 Kinnman N, Lindblad A, Housset C, Buentke E, Scheynius A, Strandvik B, Hultcrantz R. Expression of cystic fibrosis transmembrane conductance regulator in liver tissue from patients with cystic fibrosis. Hepatology 2000;32:334-40. [PMID: 10915740 DOI: 10.1053/jhep.2000.9111] [Cited by in Crossref: 49] [Cited by in F6Publishing: 38] [Article Influence: 2.2] [Reference Citation Analysis]
64 Sivam S, Al-Hindawi Y, Di Michiel J, Moriarty C, Spratt P, Jansz P, Malouf M, Plit M, Pleass H, Havryk A, Bowen D, Haber P, Glanville AR, Bye PT. Liver and lung transplantation in cystic fibrosis: an adult cystic fibrosis centre's experience. Intern Med J 2016;46:852-4. [PMID: 27405894 DOI: 10.1111/imj.13126] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
65 Colombo C. Liver disease in cystic fibrosis. Curr Opin Pulm Med. 2007;13:529-536. [PMID: 17901760 DOI: 10.1097/mcp.0b013e3282f10a16] [Cited by in Crossref: 115] [Cited by in F6Publishing: 36] [Article Influence: 8.2] [Reference Citation Analysis]
66 Calvopina DA, Chatfield MD, Weis A, Coleman MA, Fernandez-rojo MA, Noble C, Ramm LE, Leung DH, Lewindon PJ, Ramm GA. MicroRNA Sequencing Identifies a Serum MicroRNA Panel, Which Combined With Aspartate Aminotransferase to Platelet Ratio Index Can Detect and Monitor Liver Disease in Pediatric Cystic Fibrosis: Hepatology. Hepatology 2018;68:2301-16. [DOI: 10.1002/hep.30156] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
67 Cutting GR, Engelhardt J, Zeitlin PL. Genetics and Pathophysiology of Cystic Fibrosis. Kendig's Disorders of the Respiratory Tract in Children. Elsevier; 2019. pp. 757-768.e6. [DOI: 10.1016/b978-0-323-44887-1.00049-3] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
68 Aqul A, Jonas MM, Harney S, Raza R, Sawicki GS, Mitchell PD, Fawaz R. Correlation of Transient Elastography With Severity of Cystic Fibrosis-related Liver Disease. J Pediatr Gastroenterol Nutr 2017;64:505-11. [PMID: 27782957 DOI: 10.1097/MPG.0000000000001448] [Cited by in Crossref: 29] [Cited by in F6Publishing: 9] [Article Influence: 5.8] [Reference Citation Analysis]
69 Seia MA, Stege PW, Pereira SV, De Vito IE, Raba J, Messina GA. Silica nanoparticle-based microfluidic immunosensor with laser-induced fluorescence detection for the quantification of immunoreactive trypsin. Analytical Biochemistry 2014;463:31-7. [DOI: 10.1016/j.ab.2014.06.016] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
70 Gooding I, Dondos V, Gyi KM, Hodson M, Westaby D. Variceal hemorrhage and cystic fibrosis: Outcomes and implications for liver transplantation. Liver Transpl 2005;11:1522-6. [DOI: 10.1002/lt.20465] [Cited by in Crossref: 48] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
71 Van Biervliet S, Verdievel H, Vande Velde S, De Bruyne R, De Looze D, Verhelst X, Geerts A, Robberecht E, Van Vlierberghe H. Longitudinal Transient Elastography Measurements Used in Follow-up for Patients with Cystic Fibrosis. Ultrasound in Medicine & Biology 2016;42:848-54. [DOI: 10.1016/j.ultrasmedbio.2015.11.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
72 Garcia AM, Dorsey J. Nonpulmonary Manifestations of Cystic Fibrosis. Kendig's Disorders of the Respiratory Tract in Children. Elsevier; 2019. pp. 788-799.e3. [DOI: 10.1016/b978-0-323-44887-1.00052-3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
73 Mendizabal M, Reddy KR, Cassuto J, Olthoff KM, Faust TW, Makar GA, Rand EB, Shaked A, Abt PL. Liver transplantation in patients with cystic fibrosis: Analysis of united network for organ sharing data: Liver Transplantation in Patients with Cystic Fibrosis. Liver Transpl 2011;17:243-50. [DOI: 10.1002/lt.22240] [Cited by in Crossref: 53] [Cited by in F6Publishing: 41] [Article Influence: 4.8] [Reference Citation Analysis]
74 Shankar S, Bolia R, Hodgson A, Bishop JR, Evans HM, Oliver MR. Combined liver and pancreas transplantation in two children with cystic fibrosis-First experience in Australia and New Zealand. Pediatr Transplant 2018;22:e13234. [DOI: 10.1111/petr.13234] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
75 Munck A, Navarro J, Debray D, Turck D. Prise en charge digestive et nutritionnelle. Archives de Pédiatrie 2001;8:838-55. [DOI: 10.1016/s0929-693x(01)80005-1] [Cited by in Crossref: 8] [Article Influence: 0.4] [Reference Citation Analysis]
76 Rosen BH, Chanson M, Gawenis LR, Liu J, Sofoluwe A, Zoso A, Engelhardt JF. Animal and model systems for studying cystic fibrosis. J Cyst Fibros 2018;17:S28-34. [PMID: 28939349 DOI: 10.1016/j.jcf.2017.09.001] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 8.6] [Reference Citation Analysis]
77 Ayoub F, Trillo-Alvarez C, Morelli G, Lascano J. Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease. World J Hepatol 2018; 10(1): 34-40 [PMID: 29399276 DOI: 10.4254/wjh.v10.i1.34] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
78 Olivier AK, Yi Y, Sun X, Sui H, Liang B, Hu S, Xie W, Fisher JT, Keiser NW, Lei D, Zhou W, Yan Z, Li G, Evans TI, Meyerholz DK, Wang K, Stewart ZA, Norris AW, Engelhardt JF. Abnormal endocrine pancreas function at birth in cystic fibrosis ferrets. J Clin Invest 2012;122:3755-68. [PMID: 22996690 DOI: 10.1172/JCI60610] [Cited by in Crossref: 93] [Cited by in F6Publishing: 61] [Article Influence: 9.3] [Reference Citation Analysis]
79 Torbenson M, Yang SQ, Liu HZ, Huang J, Gage W, Diehl AM. STAT-3 overexpression and p21 up-regulation accompany impaired regeneration of fatty livers. Am J Pathol. 2002;161:155-161. [PMID: 12107100 DOI: 10.1016/s0002-9440(10)64167-3] [Cited by in Crossref: 71] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
80 Mascarenhas MR. Treatment of gastrointestinal problems in cystic fibrosis. Curr Treat Options Gastro 2003;6:427-41. [DOI: 10.1007/s11938-003-0045-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
81 Gabolde M, Hubert D, Guilloud-Bataille M, Lenaerts C, Feingold J, Besmond C. The mannose binding lectin gene influences the severity of chronic liver disease in cystic fibrosis. J Med Genet 2001;38:310-1. [PMID: 11333866 DOI: 10.1136/jmg.38.5.310] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 1.8] [Reference Citation Analysis]
82 Calvopina DA, Coleman MA, Lewindon PJ, Ramm GA. Function and Regulation of MicroRNAs and Their Potential as Biomarkers in Paediatric Liver Disease. Int J Mol Sci 2016;17:E1795. [PMID: 27801781 DOI: 10.3390/ijms17111795] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
83 Schwarz KB, Rosensweig J, Sharma S, Jones L, Durant M, Potter C, Narkewicz MR. Plasma markers of platelet activation in cystic fibrosis liver and lung disease. J Pediatr Gastroenterol Nutr 2003;37:187-91. [PMID: 12883307 DOI: 10.1097/00005176-200308000-00019] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
84 Kitson MT, Kemp WW, Iser DM, Paul E, Wilson JW, Roberts SK. Utility of transient elastography in the non-invasive evaluation of cystic fibrosis liver disease. Liver Int 2013;33:698-705. [PMID: 23432782 DOI: 10.1111/liv.12113] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
85 Dana J, Debray D, Beaufrère A, Hillaire S, Fabre M, Reinhold C, Baumert T, Berteloot L, Vilgrain V. Cystic fibrosis-related liver disease: clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies. J Hepatol 2021:S0168-8278(21)02115-2. [PMID: 34678405 DOI: 10.1016/j.jhep.2021.09.042] [Reference Citation Analysis]
86 Collardeau-Frachon S, Bouvier R, Le Gall C, Rivet C, Cabet F, Bellon G, Lachaux A, Scoazec JY. Unexpected diagnosis of cystic fibrosis at liver biopsy: a report of four pediatric cases. Virchows Arch 2007;451:57-64. [PMID: 17554556 DOI: 10.1007/s00428-007-0434-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
87 Ishak KG. Inherited metabolic diseases of the liver. Clin Liver Dis. 2002;6:455-479, viii. [PMID: 12122865 DOI: 10.1016/s1089-3261(02)00013-2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
88 Sinaasappel M, Stern M, Littlewood J, Wolfe S, Steinkamp G, Heijerman HG, Robberecht E, Döring G. Nutrition in patients with cystic fibrosis: a European Consensus. J Cyst Fibros 2002;1:51-75. [PMID: 15463811 DOI: 10.1016/s1569-1993(02)00032-2] [Cited by in Crossref: 295] [Cited by in F6Publishing: 45] [Article Influence: 16.4] [Reference Citation Analysis]
89 Kappler M, Espach C, Schweiger-Kabesch A, Lang T, Hartl D, Hector A, Glasmacher C, Griese M. Ursodeoxycholic acid therapy in cystic fibrosis liver disease--a retrospective long-term follow-up case-control study. Aliment Pharmacol Ther 2012;36:266-73. [PMID: 22670841 DOI: 10.1111/j.1365-2036.2012.05177.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
90 Gossard AA, Talwalkar JA. Cholestatic liver disease. Med Clin North Am 2014;98:73-85. [PMID: 24266915 DOI: 10.1016/j.mcna.2013.09.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
91 Hansen K, Horslen S. Metabolic liver disease in children. Liver Transpl 2008;14:713-33. [PMID: 18433056 DOI: 10.1002/lt.21520] [Cited by in Crossref: 38] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
92 Leeuwen L, Fitzgerald DA, Gaskin KJ. Liver disease in cystic fibrosis. Paediatr Respir Rev. 2013;Jun 13; Epub ahead of print. [PMID: 23769887 DOI: 10.1016/j.prrv.2013.05.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
93 Strandvik B, O Neal WK, Ali MA, Hammar U. Low linoleic and high docosahexaenoic acids in a severe phenotype of transgenic cystic fibrosis mice. Exp Biol Med (Maywood) 2018;243:496-503. [PMID: 29513100 DOI: 10.1177/1535370218758605] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
94 Bhardwaj S, Canlas K, Kahi C, Temkit M, Molleston J, Ober M, Howenstine M, Kwo PY. Hepatobiliary abnormalities and disease in cystic fibrosis: epidemiology and outcomes through adulthood. J Clin Gastroenterol. 2009;43:858-864. [PMID: 19525864 DOI: 10.1097/mcg.0b013e31819e8bbd] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
95 Girodon E, Sternberg D, Chazouillères O, Cazeneuve C, Huot D, Calmus Y, Poupon R, Goossens M, Housset C. Cystic fibrosis transmembrane conductance regulator (CFTR) gene defects in patients with primary sclerosing cholangitis. J Hepatol 2002;37:192-7. [PMID: 12127423 DOI: 10.1016/s0168-8278(02)00161-7] [Cited by in Crossref: 38] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
96 Nascimento FS, Sena NA, Ferreira TDA, Marques CDF, Silva LR, Souza EL. Hepatobiliary disease in children and adolescents with cystic fibrosis. J Pediatr (Rio J) 2018;94:504-10. [PMID: 28888897 DOI: 10.1016/j.jped.2017.07.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
97 Mayer-Hamblett N, Kloster M, Ramsey BW, Narkewicz MR, Saiman L, Goss CH. Incidence and clinical significance of elevated liver function tests in cystic fibrosis clinical trials. Contemp Clin Trials 2013;34:232-8. [PMID: 23200843 DOI: 10.1016/j.cct.2012.11.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
98 Lai HS, Lin WH, Chen PR, Wu HC, Lee PH, Chen WJ. Effects of a high-fiber diet on hepatocyte apoptosis and liver regeneration after partial hepatectomy in rats with fatty liver. JPEN J Parenter Enteral Nutr. 2005;29:401-407. [PMID: 16224031 DOI: 10.1177/0148607105029006401] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
99 Colombo C, Alicandro G. Liver Disease in Cystic Fibrosis: Illuminating the Black Box. Hepatology 2019;69:1379-81. [PMID: 30191579 DOI: 10.1002/hep.30255] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
100 Palaniappan SK, Than NN, Thein AW, van Mourik I. Interventions for preventing and managing advanced liver disease in cystic fibrosis. Cochrane Database Syst Rev 2020;3:CD012056. [PMID: 32227478 DOI: 10.1002/14651858.CD012056.pub3] [Reference Citation Analysis]
101 Curry MP, Hegarty JE. The gallbladder and biliary tract in cystic fibrosis. Curr Gastroenterol Rep 2005;7:147-53. [PMID: 15802104 DOI: 10.1007/s11894-005-0053-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
102 Feranchak AP. Hepatobiliary complications of cystic fibrosis. Curr Gastroenterol Rep 2004;6:231-9. [DOI: 10.1007/s11894-004-0013-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
103 Corbett K, Kelleher S, Rowland M, Daly L, Drumm B, Canny G, Greally P, Hayes R, Bourke B. Cystic fibrosis-associated liver disease: a population-based study. J Pediatr 2004;145:327-32. [PMID: 15343185 DOI: 10.1016/j.jpeds.2004.05.051] [Cited by in Crossref: 58] [Cited by in F6Publishing: 44] [Article Influence: 3.2] [Reference Citation Analysis]
104 Lemaitre C, Dominique S, Billoud E, Eliezer M, Montialoux H, Quillard M, Riachi G, Koning E, Morisse-Pradier H, Savoye G. Relevance of 3D Cholangiography and Transient Elastography to Assess Cystic Fibrosis-Associated Liver Disease? Can Respir J. 2016;2016:4592702. [PMID: 27445541 DOI: 10.1155/2016/4592702] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
105 Chryssostalis A, Hubert D, Coste J, Kanaan R, Burgel PR, Desmazes-Dufeu N, Soubrane O, Dusser D, Sogni P. Liver disease in adult patients with cystic fibrosis: a frequent and independent prognostic factor associated with death or lung transplantation. J Hepatol 2011;55:1377-82. [PMID: 21703187 DOI: 10.1016/j.jhep.2011.03.028] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
106 Desai C, Gruessner A, Habib S, Gruessner R, Khan K. Survival of Cystic Fibrosis Patients Undergoing Liver and Liver-Lung Transplantations. Transplantation Proceedings 2013;45:290-2. [DOI: 10.1016/j.transproceed.2012.02.033] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
107 Hudson VM. Rethinking cystic fibrosis pathology: the critical role of abnormal reduced glutathione (GSH) transport caused by CFTR mutation. Free Radical Biology and Medicine 2001;30:1440-61. [DOI: 10.1016/s0891-5849(01)00530-5] [Cited by in Crossref: 112] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
108 Roberts EA. Steatohepatitis in children. Best Practice & Research Clinical Gastroenterology 2002;16:749-65. [DOI: 10.1053/bega.2002.0331] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 2.0] [Reference Citation Analysis]
109 Siegel MJ, Freeman AJ, Ye W, Palermo JJ, Molleston JP, Paranjape SM, Stoll J, Leung DH, Masand P, Karmazyn B, Harned R, Ling SC, Navarro OM, Karnsakul W, Alazraki A, Schwarzenberg SJ, Seidel FG, Towbin A, Alonso EM, Nicholas JL, Murray KF, Otto RK, Sherker AH, Magee JC, Narkewicz MR; CFLD Network. Heterogeneous Liver on Research Ultrasound Identifies Children with Cystic Fibrosis at High Risk of Advanced Liver Disease: Interim Results of a Prospective Observational Case-Controlled Study. J Pediatr 2020;219:62-69.e4. [PMID: 32061406 DOI: 10.1016/j.jpeds.2019.12.033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
110 Van Biervliet S, Van Biervliet JP, Robberecht E, Christophe A. Fatty acid composition of serum phospholipids in cystic fibrosis (CF) patients with or without CF related liver disease. Clin Chem Lab Med. 2010;48:1751-1755. [PMID: 20961201 DOI: 10.1515/cclm.2010.336] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
111 Bolia R, Ooi CY, Lewindon P, Bishop J, Ranganathan S, Harrison J, Ford K, van der Haak N, Oliver MR. Practical approach to the gastrointestinal manifestations of cystic fibrosis. J Paediatr Child Health 2018;54:609-19. [PMID: 29768684 DOI: 10.1111/jpc.13921] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
112 Desmond CP, Wilson J, Bailey M, Clark D, Roberts SK. The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid. Liver Int 2007;27:1402-8. [PMID: 18036103 DOI: 10.1111/j.1478-3231.2007.01570.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
113 Miller MR, Sokol RJ, Narkewicz MR, Sontag MK. Pulmonary function in individuals who underwent liver transplantation: From the US cystic fibrosis foundation registry: Pulmonary Function in Individuals with Cystic Fibrosis. Liver Transpl 2012;18:585-93. [DOI: 10.1002/lt.23389] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
114 Mailliard ME, Gollan JL. Metabolic liver disease in the young adult. Best Practice & Research Clinical Gastroenterology 2003;17:307-22. [DOI: 10.1016/s1521-6918(02)00148-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
115 Pereira TN, Lewindon PJ, Greer RM, Hoskins AC, Williamson RM, Shepherd RW, Ramm GA. Transcriptional basis for hepatic fibrosis in cystic fibrosis-associated liver disease. J Pediatr Gastroenterol Nutr 2012;54:328-35. [PMID: 22157922 DOI: 10.1097/MPG.0b013e3182432034] [Cited by in Crossref: 18] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
116 Menten R, Leonard A, Clapuyt P, Vincke P, Nicolae AC, Lebecque P. Transient elastography in patients with cystic fibrosis. Pediatr Radiol 2010;40:1231-5. [PMID: 20135110 DOI: 10.1007/s00247-009-1531-z] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 5.6] [Reference Citation Analysis]
117 Pozniak KN, Pearen MA, Pereira TN, Kramer CSM, Kalita-De Croft P, Nawaratna SK, Fernandez-Rojo MA, Gobert GN, Tirnitz-Parker JEE, Olynyk JK, Shepherd RW, Lewindon PJ, Ramm GA. Taurocholate Induces Biliary Differentiation of Liver Progenitor Cells Causing Hepatic Stellate Cell Chemotaxis in the Ductular Reaction: Role in Pediatric Cystic Fibrosis Liver Disease. Am J Pathol. 2017;187:2744-2757. [PMID: 28935574 DOI: 10.1016/j.ajpath.2017.08.024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
118 Zarei K, Meyerholz DK, Stoltz DA. Early intrahepatic duct defects in a cystic fibrosis porcine model. Physiol Rep 2021;9:e14978. [PMID: 34288572 DOI: 10.14814/phy2.14978] [Reference Citation Analysis]
119 Jackson R, Pencharz PB. Transition of care between paediatric and adult gastroenterology. Cystic fibrosis. Best Pract Res Clin Gastroenterol 2003;17:213-35. [PMID: 12676116 DOI: 10.1016/s1521-6918(02)00150-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
120 Rath T, Menendez KM, Kügler M, Hage L, Wenzel C, Schulz R, Graf J, Nährlich L, Roeb E, Roderfeld M. TIMP-1/-2 and transient elastography allow non invasive diagnosis of cystic fibrosis associated liver disease. Dig Liver Dis. 2012;44:780-787. [PMID: 22652148 DOI: 10.1016/j.dld.2012.04.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
121 Moyer K, Balistreri W. Hepatobiliary disease in patients with cystic fibrosis. Curr Opin Gastroenterol 2009;25:272-8. [PMID: 19381084 DOI: 10.1097/MOG.0b013e3283298865] [Cited by in Crossref: 67] [Cited by in F6Publishing: 15] [Article Influence: 5.2] [Reference Citation Analysis]
122 Badet F, Bellis G, De Braekeleer M, Nove Josserand R, Vital Durand D, Durieu I. Phenotype and genotype of French cystic fibrosis patients with long survival and follow-up. European Journal of Internal Medicine 2004;15:238-41. [DOI: 10.1016/j.ejim.2004.04.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
123 Ooi CY, Durie PR. Cystic fibrosis from the gastroenterologist's perspective. Nat Rev Gastroenterol Hepatol 2016;13:175-85. [DOI: 10.1038/nrgastro.2015.226] [Cited by in Crossref: 65] [Cited by in F6Publishing: 56] [Article Influence: 10.8] [Reference Citation Analysis]
124 Fiel MI, Schiano T. Ascites and variceal bleeding occurring in a 20-year-old with cystic fibrosis. Hepatology 2009;49:1773-4. [PMID: 19402110 DOI: 10.1002/hep.23001] [Reference Citation Analysis]
125 Yan Z, Stewart ZA, Sinn PL, Olsen JC, Hu J, Mccray, Jr. PB, Engelhardt JF. Ferret and Pig Models of Cystic Fibrosis: Prospects and Promise for Gene Therapy. Human Gene Therapy Clinical Development 2015. [DOI: 10.1089/hum.2014.154] [Reference Citation Analysis]
126 Fustik S, Jacovska T, Spirevska L, Koceva S. Protein-energy malnutrition as the first manifestation of cystic fibrosis in infancy. Pediatrics International 2009;51:678-83. [DOI: 10.1111/j.1442-200x.2009.02855.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
127 Lu BR, Esquivel CO. A review of abdominal organ transplantation in cystic fibrosis. Pediatr Transplant 2010;14:954-60. [PMID: 20946451 DOI: 10.1111/j.1399-3046.2010.01412.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
128 Kamal N, Surana P, Koh C. Liver disease in patients with cystic fibrosis. Curr Opin Gastroenterol 2018;34:146-51. [PMID: 29438119 DOI: 10.1097/MOG.0000000000000432] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
129 Toledano MB, Mukherjee SK, Howell J, Westaby D, Khan SA, Bilton D, Simmonds NJ. The emerging burden of liver disease in cystic fibrosis patients: A UK nationwide study. PLoS One 2019;14:e0212779. [PMID: 30947265 DOI: 10.1371/journal.pone.0212779] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
130 Cook NL, Pereira TN, Lewindon PJ, Shepherd RW, Ramm GA. Circulating MicroRNAs as Noninvasive Diagnostic Biomarkers of Liver Disease in Children With Cystic Fibrosis. Journal of Pediatric Gastroenterology & Nutrition 2015;60:247-54. [DOI: 10.1097/mpg.0000000000000600] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
131 Werner A, Havinga R, Bos T, Bloks VW, Kuipers F, Verkade HJ. Essential fatty acid deficiency in mice is associated with hepatic steatosis and secretion of large VLDL particles. American Journal of Physiology-Gastrointestinal and Liver Physiology 2005;288:G1150-8. [DOI: 10.1152/ajpgi.00456.2004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
132 Bernhard W, Lange R, Graepler-Mainka U, Engel C, Machann J, Hund V, Shunova A, Hector A, Riethmüller J. Choline Supplementation in Cystic Fibrosis-The Metabolic and Clinical Impact. Nutrients 2019;11:E656. [PMID: 30889905 DOI: 10.3390/nu11030656] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
133 Akata D, Akhan O. Liver manifestations of cystic fibrosis. Eur J Radiol 2007;61:11-7. [PMID: 17174503 DOI: 10.1016/j.ejrad.2006.11.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
134 Nightingale S, O'Loughlin EV, Dorney SF, Shun A, Verran DJ, Strasser SI, McCaughan GW, Jermyn V, Van Asperen P, Gaskin KJ, Stormon MO. Isolated liver transplantation in children with cystic fibrosis--an Australian experience. Pediatr Transplant 2010;14:779-85. [PMID: 20557476 DOI: 10.1111/j.1399-3046.2010.01341.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
135 Sakiani S, Kleiner DE, Heller T, Koh C. Hepatic Manifestations of Cystic Fibrosis. Clin Liver Dis 2019;23:263-77. [PMID: 30947876 DOI: 10.1016/j.cld.2018.12.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
136 Colombo C, Russo MC, Zazzeron L, Romano G. Liver disease in cystic fibrosis. J Pediatr Gastroenterol Nutr 2006;43 Suppl 1:S49-55. [PMID: 16819402 DOI: 10.1097/01.mpg.0000226390.02355.52] [Cited by in Crossref: 67] [Cited by in F6Publishing: 45] [Article Influence: 4.5] [Reference Citation Analysis]
137 Trauner M, Boyer JL. Cholestatic syndromes. Curr Opin Gastroenterol 2000;16:239-50. [PMID: 17023881 DOI: 10.1097/00001574-200005000-00006] [Reference Citation Analysis]
138 Højte C, Jørgensen MH, Jensen F, Katzenstein TL, Skov M. Extended Screening for Cystic Fibrosis-related Liver Disease Including Elastography in Children and Adolescents. J Pediatr Gastroenterol Nutr 2020;71:663-8. [PMID: 33093375 DOI: 10.1097/MPG.0000000000002872] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 Colombo C, Battezzati PM, Crosignani A, Morabito A, Costantini D, Padoan R, Giunta A. Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome. Hepatology. 2002;36:1374-1382. [PMID: 12447862 DOI: 10.1002/hep.1840360613] [Cited by in Crossref: 149] [Cited by in F6Publishing: 79] [Article Influence: 7.8] [Reference Citation Analysis]
140 Fiorotto R, Amenduni M, Mariotti V, Fabris L, Spirli C, Strazzabosco M. Src kinase inhibition reduces inflammatory and cytoskeletal changes in ΔF508 human cholangiocytes and improves cystic fibrosis transmembrane conductance regulator correctors efficacy. Hepatology 2018;67:972-88. [PMID: 28836688 DOI: 10.1002/hep.29400] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
141 Feranchak AP, Doctor RB, Troetsch M, Brookman K, Johnson SM, Fitz JG. Calcium-dependent regulation of secretion in biliary epithelial cells: the role of apamin-sensitive SK channels. Gastroenterology. 2004;127:903-913. [PMID: 15362045 DOI: 10.1053/j.gastro.2004.06.047] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
142 A-Kader HH. Lysosomal acid lipase deficiency: a form of non-obese fatty liver disease (NOFLD). Expert Rev Gastroenterol Hepatol 2017;11:911-24. [PMID: 28612634 DOI: 10.1080/17474124.2017.1343144] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
143 Debray D, Corvol H, Housset C. Modifier genes in cystic fibrosis-related liver disease. Curr Opin Gastroenterol 2019;35:88-92. [PMID: 30585791 DOI: 10.1097/MOG.0000000000000508] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 8.5] [Reference Citation Analysis]
144 Sağlam D, Demirbaş F, Bilgici MC, Yücel S, Çaltepe G, Eren E. Can Point Shear Wave Elastography Be Used as an Early Indicator of Involvement?: Evaluation of the Pancreas and Liver in Children With Cystic Fibrosis. J Ultrasound Med 2020;39:1769-76. [PMID: 32309883 DOI: 10.1002/jum.15281] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
145 Nash KL, Allison ME, McKeon D, Lomas DJ, Haworth CS, Bilton D, Alexander GJ. A single centre experience of liver disease in adults with cystic fibrosis 1995-2006. J Cyst Fibros. 2008;7:252-257. [PMID: 18042441 DOI: 10.1016/j.jcf.2007.10.004] [Cited by in Crossref: 55] [Cited by in F6Publishing: 41] [Article Influence: 3.7] [Reference Citation Analysis]
146 Leung DH, Ye W, Molleston JP, Weymann A, Ling S, Paranjape SM, Romero R, Schwarzenberg SJ, Palermo J, Alonso EM, Murray KF, Marshall BC, Sherker AH, Siegel MJ, Krishnamurthy R, Harned R, Karmazyn B, Magee JC, Narkewicz MR; Cystic Fibrosis Liver Disease Network (CFLD NET). Baseline Ultrasound and Clinical Correlates in Children with Cystic Fibrosis. J Pediatr 2015;167:862-868.e2. [PMID: 26254836 DOI: 10.1016/j.jpeds.2015.06.062] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
147 Karnsakul W, Wasuwanich P, Ingviya T, Vasilescu A, Carson KA, Mogayzel PJ, Schwarz KB. A longitudinal assessment of non-invasive biomarkers to diagnose and predict cystic fibrosis-associated liver disease.J Cyst Fibros. 2020;19:546-552. [PMID: 32482593 DOI: 10.1016/j.jcf.2020.05.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
148 Gominon AL, Frison E, Hiriart JB, Vergniol J, Clouzeau H, Enaud R, Bui S, Fayon M, de Ledinghen V, Lamireau T. Assessment of Liver Disease Progression in Cystic Fibrosis Using Transient Elastography. J Pediatr Gastroenterol Nutr 2018;66:455-60. [PMID: 29112089 DOI: 10.1097/MPG.0000000000001822] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
149 Ronan NJ, Elborn JS, Plant BJ. Current and emerging comorbidities in cystic fibrosis. Presse Med 2017;46:e125-38. [PMID: 28554721 DOI: 10.1016/j.lpm.2017.05.011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 6.4] [Reference Citation Analysis]
150 Kelly T, Buxbaum J. Gastrointestinal Manifestations of Cystic Fibrosis. Dig Dis Sci 2015;60:1903-13. [DOI: 10.1007/s10620-015-3546-7] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 7.1] [Reference Citation Analysis]
151 Williams SM, Goodman R, Thomson A, Mchugh K, Lindsell DR. Ultrasound Evaluation of Liver Disease in Cystic Fibrosis as Part of an Annual Assessment Clinic: A 9-year Review. Clinical Radiology 2002;57:365-70. [DOI: 10.1053/crad.2001.0861] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
152 Schaedel C, de Monestrol I, Hjelte L, Johannesson M, Kornfält R, Lindblad A, Strandvik B, Wahlgren L, Holmberg L. Predictors of deterioration of lung function in cystic fibrosis*: CFTR Genotype in Lung Function in CF. Pediatr Pulmonol 2002;33:483-91. [DOI: 10.1002/ppul.10100] [Cited by in Crossref: 129] [Cited by in F6Publishing: 119] [Article Influence: 6.5] [Reference Citation Analysis]
153 Roullet-renoleau N. Question 2 Quelle stratégie pour maintenir un état nutritionnel optimal? Influence de 1' état nutritionnel sur 1' evolution de la mucoviscidose: aspects physiopathologique, epidemiologique et clinique des troubles nutritionnels. Archives de Pédiatrie 2003;10:449-52. [DOI: 10.1016/s0929-693x(03)90009-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
154 Vo HD, Xu J, Rabinowitz SS, Fisher SE, Schwarz SM. The Liver in Pediatric Gastrointestinal Disease. Journal of Pediatric Gastroenterology & Nutrition 2014;59:288-99. [DOI: 10.1097/mpg.0000000000000444] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
155 Cottart CH, Bonvin E, Rey C, Wendum D, Bernaudin JF, Dumont S, Lasnier E, Debray D, Clément A, Housset C, Bonora M. Impact of nutrition on phenotype in CFTR-deficient mice. Pediatr Res 2007;62:528-32. [PMID: 17805210 DOI: 10.1203/PDR.0b013e318155a61d] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
156 Rath T, Hage L, Kügler M, Menendez Menendez K, Zachoval R, Naehrlich L, Schulz R, Roderfeld M, Roeb E. Serum proteome profiling identifies novel and powerful markers of cystic fibrosis liver disease. PLoS One. 2013;8:e58955. [PMID: 23516586 DOI: 10.1371/journal.pone.0058955] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
157 Woodruff SA, Sontag MK, Accurso FJ, Sokol RJ, Narkewicz MR. Prevalence of elevated liver enzymes in children with cystic fibrosis diagnosed by newborn screen. Journal of Cystic Fibrosis 2017;16:139-45. [DOI: 10.1016/j.jcf.2016.08.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
158 Witters P, De Boeck K, Dupont L, Proesmans M, Vermeulen F, Servaes R, Verslype C, Laleman W, Nevens F, Hoffman I, Cassiman D. Non-invasive liver elastography (Fibroscan) for detection of cystic fibrosis-associated liver disease. J Cyst Fibros 2009;8:392-9. [PMID: 19733131 DOI: 10.1016/j.jcf.2009.08.001] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 4.2] [Reference Citation Analysis]
159 Olivier AK, Gibson-Corley KN, Meyerholz DK. Animal models of gastrointestinal and liver diseases. Animal models of cystic fibrosis: gastrointestinal, pancreatic, and hepatobiliary disease and pathophysiology. Am J Physiol Gastrointest Liver Physiol 2015;308:G459-71. [PMID: 25591863 DOI: 10.1152/ajpgi.00146.2014] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
160 Colombo C, Alicandro G, Oliver M, Lewindon PJ, Ramm GA, Ooi CY, Alghisi F, Kashirskaya N, Kondratyeva E, Corti F, Padoan R, Asherova I, Evans H, de Monestrol I, Strandvik B, Lindblad A; CF UDCA study group. Ursodeoxycholic acid and liver disease associated with cystic fibrosis: A multicenter cohort study. J Cyst Fibros 2021:S1569-1993(21)00090-4. [PMID: 33814323 DOI: 10.1016/j.jcf.2021.03.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
161 Fisher JT, Zhang Y, Engelhardt JF. Comparative biology of cystic fibrosis animal models. Methods Mol Biol. 2011;742:311-334. [PMID: 21547741 DOI: 10.1007/978-1-61779-120-8_19] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 5.1] [Reference Citation Analysis]
162 Gronowitz E, Lorentzon M, Ohlsson C, Mellström D, Strandvik B. Docosahexaenoic acid is associated with endosteal circumference in long bones in young males with cystic fibrosis. Br J Nutr 2008;99:160-7. [DOI: 10.1017/s000711450780105x] [Cited by in Crossref: 12] [Article Influence: 0.8] [Reference Citation Analysis]
163 Debray D, El Mourabit H, Merabtene F, Brot L, Ulveling D, Chrétien Y, Rainteau D, Moszer I, Wendum D, Sokol H, Housset C. Diet-Induced Dysbiosis and Genetic Background Synergize With Cystic Fibrosis Transmembrane Conductance Regulator Deficiency to Promote Cholangiopathy in Mice. Hepatol Commun 2018;2:1533-49. [PMID: 30556040 DOI: 10.1002/hep4.1266] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
164 Boëlle PY, Debray D, Guillot L, Clement A, Corvol H; French CF Modifier Gene Study Investigators. Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients. Hepatology 2019;69:1648-56. [PMID: 30058245 DOI: 10.1002/hep.30148] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 9.5] [Reference Citation Analysis]
165 Hirche TO, Knoop C, Hebestreit H, Shimmin D, Solé A, Elborn JS, Ellemunter H, Aurora P, Hogardt M, Wagner TO; ECORN-CF Study Group. Practical guidelines: lung transplantation in patients with cystic fibrosis. Pulm Med 2014;2014:621342. [PMID: 24800072 DOI: 10.1155/2014/621342] [Cited by in Crossref: 45] [Cited by in F6Publishing: 31] [Article Influence: 5.6] [Reference Citation Analysis]
166 Kelleher T, Staunton M, O'Mahony S, McCormick PA. Advanced hepatocellular carcinoma associated with cystic fibrosis.Eur J Gastroenterol Hepatol. 2005;17:1123-1124. [PMID: 16148560 DOI: 10.1097/00042737-200510000-00018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
167 Flass T, Narkewicz MR. Cirrhosis and other liver disease in cystic fibrosis. J Cyst Fibros. 2013;12:116-124. [PMID: 23266093 DOI: 10.1016/j.jcf.2012.11.010] [Cited by in Crossref: 95] [Cited by in F6Publishing: 79] [Article Influence: 9.5] [Reference Citation Analysis]
168 Koh C, Sakiani S, Surana P, Zhao X, Eccleston J, Kleiner DE, Herion D, Liang TJ, Hoofnagle JH, Chernick M, Heller T. Adult-onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity. Hepatology. 2017;66:591-601. [PMID: 28422310 DOI: 10.1002/hep.29217] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 10.2] [Reference Citation Analysis]
169 Flemming G, Baumann U, Richter N, Vondran F, Tümmler B, Dittrich AM, Müller C, Vogel M, Pfister ED. Survival Benefits Following Liver Transplantation: A Matched-pair Analysis in Pediatric Patients With Cystic Fibrosis. J Pediatr Gastroenterol Nutr 2021;73:385-90. [PMID: 34091543 DOI: 10.1097/MPG.0000000000003194] [Reference Citation Analysis]
170 Yan Z, Stewart ZA, Sinn PL, Olsen JC, Hu J, McCray PB Jr, Engelhardt JF. Ferret and pig models of cystic fibrosis: prospects and promise for gene therapy. Hum Gene Ther Clin Dev 2015;26:38-49. [PMID: 25675143 DOI: 10.1089/humc.2014.154] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
171 Kutney K, Donnola SB, Flask CA, Gubitosi-Klug R, O’Riordan M, McBennett K, Sferra TJ, Kaminski B. Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients. World J Hepatol 2019; 11(12): 761-772 [PMID: 31966908 DOI: 10.4254/wjh.v11.i12.761] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
172 Parisi GF, Di Dio G, Franzonello C, Gennaro A, Rotolo N, Lionetti E, Leonardi S. Liver disease in cystic fibrosis: an update. Hepat Mon. 2013;13:e11215. [PMID: 24171010 DOI: 10.5812/hepatmon.11215] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
173 Colombo C, Battezzati PM. Liver involvement in cystic fibrosis: primary organ damage or innocent bystander? J Hepatol 2004;41:1041-4. [PMID: 15582140 DOI: 10.1016/j.jhep.2004.10.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
174 Hansen K, Horslen S. Metabolic liver disease in children. Liver Transpl 2008;14:391-411. [DOI: 10.1002/lt.21470] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
175 Alisi A, de Vito R, Monti L, Nobili V. Liver fibrosis in paediatric liver diseases. Best Pract Res Clin Gastroenterol. 2011;25:259-268. [PMID: 21497743 DOI: 10.1016/j.bpg.2011.02.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
176 Kassel CA, Fremming BA, Brown BA, Markin NW. 2019 Clinical Update in Liver Transplantation. J Cardiothorac Vasc Anesth 2021;35:1495-502. [PMID: 32173208 DOI: 10.1053/j.jvca.2020.01.056] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
177 Schneider EK, Reyes-Ortega F, Li J, Velkov T. Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor? Clin Pharmacol Ther 2017;101:130-41. [PMID: 27804127 DOI: 10.1002/cpt.548] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
178 Scott J, Jones AM, Piper Hanley K, Athwal VS. Review article: epidemiology, pathogenesis and management of liver disease in adults with cystic fibrosis. Aliment Pharmacol Ther 2022. [PMID: 35048397 DOI: 10.1111/apt.16749] [Reference Citation Analysis]
179 Wise P, Wright J, Chapman W, Drinkwater D, Slovis B, Pierson R, Pinson C. Heart-lung-liver transplant for cystic fibrosis. Transplantation Proceedings 2001;33:3568-71. [DOI: 10.1016/s0041-1345(01)02537-4] [Cited by in Crossref: 11] [Article Influence: 0.5] [Reference Citation Analysis]
180 Pereira TN, Walsh MJ, Lewindon PJ, Ramm GA. Paediatric cholestatic liver disease: Diagnosis, assessment of disease progression and mechanisms of fibrogenesis. World J Gastrointest Pathophysiol 2010; 1(2): 69-84 [PMID: 21607144 DOI: 10.4291/wjgp.v1.i2.69] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
181 Al Sinani S, Al-Mulaabed S, Al Naamani K, Sultan R. Cystic Fibrosis Liver Disease: Know More. Oman Med J 2019;34:482-9. [PMID: 31745411 DOI: 10.5001/omj.2019.90] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
182 Debray D. Question 5 Quelle prise en charge de l'átteinte hepatobiliaire au cours de la mucoviscidose? Stratégie thérapeutique spécifique de 1' atteinte hépatobiliaire au cours de la mucoviscidose. Archives de Pédiatrie 2003;10:490-4. [DOI: 10.1016/s0929-693x(03)90016-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
183 Gronowitz E, Pitkänen S, Kjellmer I, Heikinheimo M, Strandvik B. Association between serum oncofetal antigens CA 19-9 and CA 125 and clinical status in patients with cystic fibrosis. Acta Paediatr. 2003;92:1267-1271. [PMID: 14696845 DOI: 10.1111/j.1651-2227.2003.tb00495.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
184 Freudenberg F, Leonard MR, Liu SA, Glickman JN, Carey MC. Pathophysiological preconditions promoting mixed "black" pigment plus cholesterol gallstones in a DeltaF508 mouse model of cystic fibrosis. Am J Physiol Gastrointest Liver Physiol 2010;299:G205-14. [PMID: 20430874 DOI: 10.1152/ajpgi.00341.2009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
185 McCormick PA, Murphy KM. Splenomegaly, hypersplenism and coagulation abnormalities in liver disease. Baillieres Best Pract Res Clin Gastroenterol. 2000;14:1009-1031. [PMID: 11139352 DOI: 10.1053/bega.2000.0144] [Cited by in Crossref: 80] [Cited by in F6Publishing: 79] [Article Influence: 3.8] [Reference Citation Analysis]